Wu Adela, Lim Michael
From the Department of Neurosurgery, Stanford Health Care, Stanford, CA.
Cancer J. 2021;27(5):371-378. doi: 10.1097/PPO.0000000000000544.
Gliomas and glioblastoma comprise the majority of brain malignancies and are difficult to treat despite standard of care and advances in immunotherapy. The challenges of controlling glioma growth and recurrence involve the uniquely immunosuppressive tumor microenvironment and systemic blunting of immune responses. In addition to highlighting key features of glioma and glioblastoma composition and immunogenicity, this review presents several future directions for immunotherapy, such as vaccines and synergistic combination treatment regimens, to better combat these tumors.
神经胶质瘤和胶质母细胞瘤构成了大多数脑恶性肿瘤，尽管有标准治疗方法和免疫治疗的进展，但仍难以治疗。控制神经胶质瘤生长和复发的挑战涉及独特的免疫抑制肿瘤微环境和免疫反应的全身抑制。除了强调神经胶质瘤和胶质母细胞瘤的组成及免疫原性的关键特征外，本综述还提出了免疫治疗的几个未来方向，如疫苗和协同联合治疗方案，以更好地对抗这些肿瘤。
